Pulse wave velocity and carotid atherosclerosis in White and Latino patients with hypertension

BMC Cardiovascular Disorders

Edward P Havranek²  Frederick A Masoudi²  Raymond O Estacio²  Miriam Dickinson³  Elhum Karimkhani¹  Patrick Hosokawa³  Carlin S Long²  Mori J Krantz² 

[1] Cardiology Division, Denver Health Medical Center, Denver, USA;Department of Medicine, University of Colorado School of Medicine, Aurora, USA;Department of Family Medicine, University of Colorado School of Medicine, Aurora, USA

关键词: C-reactive protein;    central aortic pressure;    augmentation index;    inflammatory markers;    Latino;    carotid intima media thickness;    atherosclerosis;    hypertension;    Pulse wave velocity;   

Others  :  1086123
DOI  :  10.1186/1471-2261-11-15

 received in 2010-11-07, accepted in 2011-04-11,  发布年份 2011

【 摘 要 】

Background

Preventive cardiology has expanded beyond coronary heart disease towards prevention of a broader spectrum of cardiovascular diseases. Ethnic minorities are at proportionately greater risk for developing extracoronary vascular disease including heart failure and cerebrovascular disease.

Methods

We performed a cross sectional study of Latino and White hypertension patients in a safety-net healthcare system. Framingham risk factors, markers of inflammation (hsCRP, LPpLA2), arterial stiffness (Pulse wave velocity, augmentation index, and central aortic pressure), and endothelial function (brachial artery flow-mediated dilatation) were measured. Univariate and multivariable associations between these parameters and an index of extracoronary atherosclerosis (carotid intima media thickness) was performed.

Results

Among 177 subjects, mean age was 62 years, 67% were female, and 67% were Latino. In univariate analysis, markers associated with carotid intima media thickness (IMT) at p < 0.25 included pulse wave velocity (PWV), augmentation index (AIx), central aortic pressure (cAP), and LpPLA₂ activity rank. However, AIx, cAP, and LpPLA2 activity were not significantly associated with carotid IMT after adjusting for Framingham risk factors (all p > .10). Only PWV retained a significant association with carotid IMT independent of the Framingham general risk profile parameters (p = .016). No statistically significant interactions between Framingham and other independent variables with ethnicity (all p > .05) were observed.

Conclusion

In this safety net cohort, PWV is a potentially useful adjunctive atherosclerotic risk marker independent of traditional risk factors and irrespective of ethnicity.

【 授权许可】

   
2011 Krantz et al; licensee BioMed Central Ltd.

【 图 表 】

Figure 1.

【 参考文献 】

• [1]D'Agostino RB Sr, Vasan RS, Pencina MJ, Wolf PA, Cobain M, Massaro JM, Kannel WB: General cardiovascular risk profile for use in primary care: the Framingham Heart Study. Circulation 2008, 117:743-753.
• [2]Wilson PW, D'Agostino RB Sr, Levy D, Belanger AM, Silbershatz H, Kannel WB: Prediction of coronary heart disease using risk factor categories. Circulation 1998, 97:1837-1847.
• [3]Marma AK, Ning H, Lloyd-Jones DM: Impact of a change to global cardiovascular risk estimation in lipid-lowering guidelines: Finding from the National Health and Nutrition Examination Survey (NHANES) 2001-2006. Circulation 2009, 120:S424.
• [4]Lloyd-Jones D, Adams RJ, Brown TM, on behalf of the American Heart Association Statistics Committee and Stroke Statistics Subcommittee, et al.: Heart disease and stroke statistics--2010 update: a report from the American Heart Association. Circulation 2010, 121:e1-e170.
• [5]Ridker PM, Buring JE, Rifai N, Cook NR: Development and validation of improved algorithms for the assessment of global cardiovascular risk in women: the Reynolds Risk Score. JAMA 2007, 297:611-619.
• [6]Heffernan KS, Fahs CA, Iwamoto GA, Jae SY, Wilund KR, Woods JA, Fernhall B: Resistance exercise training reduces central blood pressure and improves microvascular function in Afrincan American and white men. Atherosclerosis 2009, 207:220-226.
• [7][http://www.censusscope.org/us/map_hispanicpop.html] webcite Accessed 25 December 2009
• [8]Hanratty R, Estacio RO, Dickinson LM, Chandramouli V, Steiner JF, Havranek EP, Latino Using Cardio Health Actions to Reduce Risk study investigators: Testing electronic algorithms to create disease registries in a safety net system. J Health Care Poor Underserved 2008, 19:452-465.
• [9]Gabow P, Eisert S, Wright R: Denver Health: a model for the integration of a public hospital and community health centers. Ann Int Med 2003, 138:143-149.
• [10]Lavi S, McConnell JP, Rihal CS, Prasad A, Mathew V, Lerman LO, Lerman A: Local production of lipoprotein-associated phospholipase A2 and lysophosphatidylcholine in the coronary circulation: association with early coronary atherosclerosis and endothelial dysfunction in humans. Circulation 2007, 115:2715-2721.
• [11]Kolodgie FD, Burke AP, Skorija KS, Ladich E, Kutys R, Makuria AT, Virmani R: Lipoprotein-associated phospholipase A2 protein expression in the natural progression of human coronary atherosclerosis. Arterioscler Thromb Vasc Biol 2006, 26:2523-2529.
• [12]Mannheim D, Herrmann J, Versari D, Gossl M, Meyer FB, McConnell JP, et al.: Enhanced expression of Lp-PLA2 and lysophosphatidylcholine in symptomatic carotid atherosclerotic plaque. Stroke 2008, 39:1448-1455.
• [13]Davidson MH, Corson MA, Alberts MJ, Anderson JL, Gorelick PB, Jones PH: Consensus panel recommendation for incorporating lipoprotein-associated phospholipase A2 testing into cardiovascular disease risk assessment guidelines. Am J Cardiol 2008, 101:51F-57F.
• [14]Clinical and Laboratory Standards Institute (CLSI): Methods comparison and bias estimation using patient samples; approved guideline-second edition. In CLSI document EP9-A2 (ISBN 1-56238-472-4). CLSI, 940 West Valley Road, Suite 1400, Wayne PA 19087-1898 USA; 2002.
• [15]O'Leary DH, Polak JF, Wolfson SK Jr, et al.: Use of sonography to evaluate carotid atherosclerosis in the elderly. The Cardiovascular Health Study. CHS Collaborative research Group. Stroke 1991, 22:1155-63.
• [16]Mitchell GF, Hwang SJ, Vasan RS, Larson MG, Pencina MJ, Hamburg NM, et al.: Arterial stiffness and cardiovascular events: the Framingham Heart Study. Circulation 2010, 121:505-511.
• [17]Kardys I, Oei HHS, van der Meer IM, Horman A, Breteler MMB, Witteman JCM: Lipoprotein-associated phospholipase A2 and measures of extracoronary atherosclerosis: the Rotterdam study. Aterioscler Thromb Vasc Biol 2006, 26:631-636.
• [18]Ridker PM, Danielson E, Fonseca FA, Genest J, Gotto AM Jr, Kastelein JJ, JUPITER Study Group, et al.: Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. N Engl J Med 2008, 359:2195-2207.
• [19]Rodondi N, Marques-Vidal P, Butler J, Sutton-Tyrrel K, Comuz J, Satterfield S, Harris T, Bauer DC, Ferrucci L, Vittinghoff E, Newman AB: Markers of atherosclerosis and inflammation for prediction of coronary heart disease in older adults. Am J Epidemiol 2010, 171:540-549.
• [20]Terai M, Ohishi M, Ito N, Takagi T, Tatara Y, Kaibe M, et al.: Comparison of arterial functional evaluations a a predictor cardiovascular events in hypertensive patients: the Non-invasive Atherosclerotic Evaluation in Hypertension (NOAH) study. Hypertens Res 2008, 31:1135-1145.
• [21]Laurent S, Cockcroft J, Van Bortel L, Boutouyrie P, Giannattasio C, Havoz D, et al.: Expert consensus document on arterial stiffness: methodological issues and clinical applications. Eur Heart J 2006, 27:2588-2605.
• [22]Vlachopoulos C, Aznaouridis K, Stefanidis C: Prediction of cardiovascular events and all-cause mortality with arterial stiffness: A systematic review and meta-analysis. J Am Coll Cardiol 2010, 55:1318-1327.
• [23]Greenland P, Alpert JS, Beller GA, Benjamin EJ, Budoff MJ, Fayad ZA, Foster E, Hlatky MA, Hodgson JMcB, Kushner FG, Lauer MS, Shaw LJ, Smith SC Jr, Taylor AJ, Weintraub WS, Wenger NK: 2010 ACCF/AHA guideline for assessment of cardiovascular risk in asymptomatic adults: executive summary: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol 2010, 56:2182-99.
• [24]Munakata M, Ito N, Nunokawa T, Yoshinaga K: Utility of automated brachial ankle pulse wave velocity measurements in hypertensive patients. Am J Hypertens 2003, 16:653-657.
• [25]Sugawara J, Hayashi K, Yokio T, Cortez-Cooper MY, DeVan AE, Anton MA, Tanaka H: Brachial-ankle pulse wave velocity: an index of central arterial stiffness? J Hum Hypertens 2005, 19:401-406.
• [26]Hoel AW, Kayssi A, Brahmanandam S, Belkin M, Conte MS, Nguyen LL: Under-representation of women and ethnic minorities in vascular surgery randomized controlled trials. J Vasc Surg 2009, 50:349-54.
• [27]Laurent S, Boutouyre P, Asmar R, Gautier I, Laloux B, Guize L, et al.: Aortic stiffness is an independent predictor of all-cause and cardiovascular disease mortality in hypertensive patients. Hypertension 2001, 37:1236-1241.
• [28]D'Agostion RB Sr, Grundy S, Sullivan LM, Wilson P, CHD Risk Prediction Group: Validation of the Framingham coronary heart disease risk prediction scores. Results of a multiple ethnic groups investigation. JAMA 2001, 286:180-187.